A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 31 May 2018
At a glance
- Drugs LY 3023414 (Primary) ; Abemaciclib; Cisplatin; Fulvestrant; Letrozole; Midazolam; Pemetrexed
- Indications Advanced breast cancer; Cancer; Lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 25 May 2018 Planned End Date changed from 1 Oct 2020 to 1 Mar 2021.
- 25 May 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.
- 10 May 2018 Planned primary completion date changed from 1 Aug 2018 to 1 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History